U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Bristol Myers Squibb has announced the U.S. Food and Drug Administration’s (FDA) approval of Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years. The approval follows the results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials, which proved the efficacy of once-daily Sotyktu compared to placebo and twice-daily Otezla® (apremilast) in achieving clearer skin. IPC Councilor April Armstrong, MD, MPH, was quoted in the press release stating, “Sotyktu has the potential to become the new standard of care oral treatment for people with moderate to severe plaque psoriasis, given its profile in helping patients achieve clearer skin as demonstrated in the POETYK PSO clinical program.”